Tedizolid

Generic Name
Tedizolid
Brand Names
Sivextro
Drug Type
Small Molecule
Chemical Formula
C17H15FN6O3
CAS Number
856866-72-3
Unique Ingredient Identifier
97HLQ82NGL
Background

Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective again...

Indication

用于特定的敏感细菌引起的成人急性细菌性皮肤和皮肤结构感染（ABSSSI）。抗菌谱为金黄色葡萄球菌(包括耐甲氧西林和甲氧西林敏感菌株)，化脓性链球菌，无乳链球菌，咽峡炎链球菌群(包括咽峡炎链球菌、中间型链球菌、星群链球菌)，粪肠球菌。

Associated Conditions
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Associated Therapies
-
Clinical Trials
Related News

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

First Posted Date
2017-06-05
Last Posted Date
2024-07-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
100
Registration Number
NCT03176134
Locations
🇺🇸

Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0129), Chicago, Illinois, United States

🇧🇷

Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0277), Recife, Pernambuco, Brazil

🇧🇬

UMHAT Deva Maria ( Site 0333), Burgas, Bulgaria

and more 55 locations

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

Phase 2
Completed
Conditions
Bone and Joint Infection
Interventions
Drug: Tedizolid
First Posted Date
2017-01-04
Last Posted Date
2023-12-13
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
44
Registration Number
NCT03009045
Locations
🇺🇸

Harbor-UCLA Medical Center, Torrance, California, United States

🇺🇸

Los Angeles BioMedical Research Institute (LA BioMed), Torrance, California, United States

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

First Posted Date
2015-12-03
Last Posted Date
2019-01-15
Lead Sponsor
Hartford Hospital
Target Recruit Count
18
Registration Number
NCT02620787
Locations
🇺🇸

Hartford Hospital, Hartford, Connecticut, United States

A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)

First Posted Date
2015-06-22
Last Posted Date
2015-08-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
18
Registration Number
NCT02477514

Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults

Phase 4
Completed
Conditions
Obesity
Interventions
Drug: Tedizolid phosphate
First Posted Date
2015-01-21
Last Posted Date
2017-03-15
Lead Sponsor
Amit.Pai
Target Recruit Count
19
Registration Number
NCT02342418

Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

Phase 3
Completed
Conditions
Pneumonia
Interventions
Drug: Linezolid
Drug: Tedizolid phosphate
First Posted Date
2013-12-24
Last Posted Date
2019-06-27
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
726
Registration Number
NCT02019420
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy